https://ictargets.com/ https://ictargets.com/news https://ictargets.com/contact-us https://ictargets.com/investors https://ictargets.com/team https://ictargets.com/about-us https://ictargets.com/what-we-do https://ictargets.com/board-of-directors https://ictargets.com/scientific-advisors-collaborators https://ictargets.com/cardiac-imaging https://ictargets.com/mri-of-liver-pancreas https://ictargets.com/news/ic-targets-as-completes-last-patient-visit-in-phase-2a-mangafodipir-trial https://ictargets.com/news/ic-targets-as-filed-a-new-patent-application-on-improved-detection-of-heart-disease https://ictargets.com/news/elin-godager-employed-as-chief-business-officer https://ictargets.com/news/ic-targets-acquires-cardinor-as-to-strengthen-heart-failure-diagnostics https://ictargets.com/news/ic-targets-patent-approved-for-granting-in-norway https://ictargets.com/news/phase-2a-trial-in-heart-failure-first-patients-dosed-with-mangafodipir https://ictargets.com/news/mangafodipir-preclinical-study-results-shared-at-cmr-symposium-oslo https://ictargets.com/news/mangafodipir-preclinical-results-presented-at-ecr-2024 https://ictargets.com/news/update-on-company-development-project-progress-and-timelines https://ictargets.com/news/ic-targets-as-is-awarded-a-nok-15-5-million-grant https://ictargets.com/news/license-agreement-with-ge-healthcare